Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGLRA1GLRBKCNK10KCNK18KCNK2KCNK3KCNK9
The experimentally established mechanism targets of Halothane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Halothane SCHEMBL443681 | 1.00 | — | — | |
| Halothane SCHEMBL25588 | 1.00 | — | — | |
| Halothane SCHEMBL1612295 | 1.00 | HSD17B10 (1.00) | — | |
| Halothane SCHEMBL1295253 | 0.96 | — | — | |
| Halothane SCHEMBL5961792 | 0.96 | HSD17B10 (0.92) | — | |
| Halothane SCHEMBL15475924 | 0.92 | — | — | |
| Halothane SCHEMBL6289622 | 0.92 | — | — | |
| Halothane SCHEMBL8902191 | 0.89 | HSD17B10 (0.79) | — | |
| Halothane SCHEMBL10725043 | 0.89 | — | — | |
| Halothane SCHEMBL9138026 | 0.80 | ALDH1A1 (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148104-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-20240122926-A1 | APELIN RECEPTOR MODULATORS FOR TREATING MUSCLE CONDITIONS | BioAge Labs, Inc. | 2024-04-18 | — | — | US | disclosed |
| WO-2024072907-A1 | APELIN RECEPTOR AGONISTS FOR TREATING MUSCLE CONDITIONS | BioAge Labs, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240092794-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4319873-A1 | APELIN RECEPTOR MODULATORS FOR TREATING AGE-RELATED MUSCLE CONDITIONS | Bioage Labs, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20240041878-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | BioAge Labs, Inc. | 2024-02-08 | — | — | US | disclosed |
| US-20240002400-A1 | ENANTIOSELECTIVE ALKENYLATION OF ALDEHYDES | AMGEN INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-11845760-B2 | PRMT5 inhibitors | AMGEN INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2004043958-A1 | FUSED HETEROCYCLIC COMPOUNDS | AMGEN INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2003-12-11 | — | — | US | disclosed |
| US-20030220339-A1 | Useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases | TULARIK INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030176694-A1 | Fused heterocyclic compounds | AMGEN INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003063796-A2 | HETEROCYCLIC ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030149108-A1 | Linked biaryl compounds | TULARIK INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003063576-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030144286-A1 | Benzimidazole derivatives | TULARIK, INC | 2003-07-31 | — | — | US | disclosed |
| WO-2003030902-A1 | IMIDAZOLE DERIVATES AS ANTI-INFLAMMATORY AGENTS | TULARIK INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003024395-A2 | LINKED BIARYL COMPOUNDS | TULARIK INC. (US) | 2003-03-27 | — | — | WO | disclosed |